

# Annual report


for the year ended 31 December 2023

## AKI Therapeutics A/S

Slotsmarken 12, 1., 2970 Hørsholm, Denmark

Registered number: 37 50 97 36

The annual report has been presented and adopted by the general meeting June 13, 2024.



Klaus Lindblad, lawyer *advokat*  
Chairman of the general meeting

## Contents

	Page
Company information	2
Management's review	3
Management's report	5
Independent auditor's report	6
Statement of comprehensive income	9
Statement of financial position	10
Statement of changes in equity	11
Cash flow statement	12
Notes	13

## Company information

---

<b>Executive management</b>	Søren Nielsen
<b>Board of directors</b>	Troels Peter Troelsen, chairman Christian Vinding Thomsen Lars Otto Uttenthal
<b>Registered number</b>	37 50 97 36
<b>Registered office</b>	Slotsmarken 12, 1. th. 2970 Hørsholm Denmark
<b>Independent auditor</b>	Grant Thornton, Godkendt Revisionspartnerselskab Stockholmsgade 45 2100 København Ø

### The Company's principal activities

AKI Therapeutics A/S is a preclinical biotechnological company that focuses 100% on developing an effective, specific treatment for acute kidney injury. The company's drug candidate is an innovative concept within this treatment area, which presents one of the biggest and most important challenges in the field of current intensive medical care.

There are currently no alternative treatments for acute kidney injury.

### Estimates and judgements

The preparation of the financial statements requires the making of estimates and judgements that effects the reporting of assets, liabilities and expenses. The estimates and judgments are reviewed on an ongoing basis. Estimates and judgements are based on historical results and on various other assumptions, which AKI Therapeutics believes to be reasonable under the circumstances. However, the actual result may differ significantly from the estimates. We believe that the accounting policies relating to development costs and deferred taxes involve estimates or judgements that could affect the reported financial position and results.

### Development in activities and financial matters

#### Financials

The result for the year is a deficit of MDK 1.7, which is in line with expectations in view of the Company's level of activity.

The Company has a satisfactory funding for 2024 to continue the operation of the Company as planned.

#### Pre-clinical programs

During the financial year the Company's therapeutic conjugate for targeting active substances to the kidneys for prevention and treatment of acute renal injury has been prepared for the *in vivo* testing in mouse models of AKI.

The Company has with success manufactured its second batch of the therapeutic conjugate (S89C-mouse-NGAL/cyclosporin A) with improved outcome.

The Company has during the financial year with success optimized and improved the AKI-mouse model using folic acid induced acute kidney injury in mice.

AKI Therapeutics A/S has a market-driven patent strategy meaning that the Company files patent applications exclusively in key markets with reasonable likelihood of receiving an enforceable patent which will secure the essential part of the expected future product revenues.

The Company has already obtained granted patent in the USA and has during the financial year also received acceptance of grant for patent in Israel on "Compositions for the prevention and treatment of acute renal injury". Examination and defense of the Company's patent applications in the other selected countries of the original filing continues.

Further, the Company has extended the portfolio of patents by filing a patent application in Hong Kong.

## Management's review

---

### Events after the end of the financial year

After the end of the financial year, the company has performed additional solubility tests, and has successfully improved the solubility and stability of the Company's therapeutic conjugate.

The Company has started the *in vivo* testing of the Company's therapeutic conjugate in mice using the Company's optimized folic acid induced AKI mouse model.

The Company has digitized its shares, which has been distributed to the shareholders accounts.

Further in 2024 the Company will expand the cooperation with the William Harvey Research Institute in London to perform further cell and animal studies giving essential data for later clinical phase I and phase II studies in humans. Through the cooperation with the William Harvey Research Institute, the Company has access to the optimal pre-clinical AKI mouse model.

## Management's report

---

The Board of Directors and the Executive management has today considered and approved the annual report of AKI Therapeutics A/S for the financial year 1 January - 31 December 2023.

The Financial Statements have been prepared in accordance with the International Financial Reporting Standards (IFRS) as adopted by the EU and further requirements in the Danish Financial Statement Act.

We consider the accounting policies used appropriate, and in our opinion the Financial Statements provide a true and fair view of the Company's assets and liabilities and its financial position at 31 December 2023 and of the Company's results of its activities and cash flow in the financial year 1 January to 31 December 2023.

We are of the opinion that the management's review includes a fair description of the issues dealt with.

The annual report is submitted for adoption by the general meeting.

Hørsholm, March 19, 2024

**Executive management**

Søren Nielsen

**Board of directors**

Troels Peter Troelsen  
Chairman

Christian Vinding Thomsen



Lars Otto Uttenthal

# Independent auditor's report

## To the shareholders of AKI Therapeutics A/S

### Opinion

We have audited the financial statements of AKI Therapeutics A/S for the financial year January 1 – December 31, 2023, which comprise statement of comprehensive income, statement of financial position, statement of changes in equity, statement of cash flows, accounting policies and notes. The financial statements are prepared in accordance with International Reporting Standards as endorsed by the EU and further requirements in the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the financial position of the company at December 31, 2023 and of the results of the company's operations and cash flows for the financial year January 1 – December 31, 2023 in accordance with International Reporting Standards as issued by the International Accounting Standards Board (IASB) and adopted by the EU and additional requirements of the Danish Financial Statements Act.

### Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the section "Auditor's responsibilities for the audit of the financial statements". We are independent of the company in accordance with International Ethical requirements for auditors (IESBA's Code of Ethics), and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Management's responsibilities for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the International Reporting Standards as adopted by EU and additional requirements Danish Financial Statements Act and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless Management either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

### Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements, as a whole, are free from material misstatement, whether due to fraud or error, and to issue an auditor's report including an opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional scepticism throughout the audit.

## Independent auditor's report

---

We also:

- Identify and assess the risks of material misstatement in the financial statements, whether due to fraud or error, design and perform audit procedures in response to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of the internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used by the management and the reasonableness of accounting estimates and related disclosures made by the management.
- Conclude on the appropriateness of the management's use of the going concern basis of accounting and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements reflect the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in the internal control that we identify during our audit.

### **Statement on the management's review**

The management is responsible for the management's Review.

Our opinion on the financial statements does not cover the management's Review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the Management's Review and in doing so, consider whether Management's Review is materially inconsistent with the financial statements or knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the Management's Review provides the information required under the Danish Financial Statements Act.



## Independent auditor's report

---

Based on the work we have performed, we conclude that Management's Review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of Management's Review.

Copenhagen, March 19, 2024

**Grant Thornton**  
**Statsautoriseret Revisionspartnerselskab**  
Company reg. no. 34 20 99 36

**Martin Bomholtz**  
State Authorised Public Accountant  
mne34117

## Statement of comprehensive income

Note	2023 DKK	2022 DKK
<b>Revenue</b>	<b>0</b>	<b>0</b>
<b>Cost of sales</b>	<b>0</b>	<b>0</b>
<b>Gross profit</b>	<b>0</b>	<b>0</b>
3 Research and development costs	-1.230.060	-451.415
3 Administrative costs	-492.061	-647.398
<b>Profit before depreciation, amortisation and impairment losses (EBITDA)</b>	<b>-1.722.121</b>	<b>-1.098.813</b>
6,7 Depreciation and amortisation of non- current assets	-300.212	-213.924
<b>Operating profit (EBIT)</b>	<b>-2.022.333</b>	<b>-1.312.738</b>
4 Financial income	46.000	0
4 Financial expenses	-15.953	-25.889
<b>Profit before tax</b>	<b>-1.992.286</b>	<b>-1.338.626</b>
5 Tax on profit for the year	283.593	221.280
<b>Net profit for the year</b>	<b>-1.708.694</b>	<b>-1.117.346</b>
Other comprehensive income	0	0
<b>Total comprehensive income</b>	<b>-1.708.694</b>	<b>-1.117.346</b>

## Statement of financial position

<b>ASSETS</b>			
Note		31-12-2023 DKK	31-12-2022 DKK
	<b>Non-current assets</b>		
6	Intangible assets	875.530	973.926
7	Right-of-use assets	422.156	290.775
	<b>Total non-current assets</b>	<b>1.297.686</b>	<b>1.264.701</b>
	<b>Current assets</b>		
8, 9	Other receivables	186.112	148.832
5	Current tax receivable	283.593	665.454
10	Cash and cash equivalents	225.562	1.242.369
	<b>Total current assets</b>	<b>695.266</b>	<b>2.056.655</b>
	<b>Total assets</b>	<b>1.992.951</b>	<b>3.321.355</b>
<b>EQUITY AND LIABILITIES</b>			
Note		31-12-2023 DKK	31-12-2022 DKK
	Share capital	525.000	525.000
	Reserve for capitalised development costs	492.811	541.630
	Retained earnings	-271.225	1.388.650
11	<b>Total equity</b>	<b>746.586</b>	<b>2.455.280</b>
	Provision for deferred tax	0	0
	<b>Total provisions</b>	<b>0</b>	<b>0</b>
	Lease liabilities	214.202	147.539
	<b>Total long-term liabilities</b>	<b>214.202</b>	<b>147.539</b>
13	Trade payables	517.208	324.925
14	Other liabilities	514.954	393.611
	<b>Total current liabilities</b>	<b>1.032.162</b>	<b>718.536</b>
	<b>Total liabilities other than provisions</b>	<b>1.246.364</b>	<b>866.075</b>
	<b>Total equity and liabilities</b>	<b>1.992.951</b>	<b>3.321.355</b>

## Statement of changes in equity

	Share capital	Reserve for capitalised development costs	Retained earnings	Total equity
<i>Statement of changes in equity</i>				
<i>01-01-2022 - 31-12-2022</i>				
Equity as at 01-01-2022	75.000	818.047	2.679.579	3.572.626
Net profit for the year	0	0	-1.117.346	-1.117.346
Capital increase	450.000	0	-450.000	0
Capitalised development costs	0	-276.417	276.417	0
	<b>450.000</b>	<b>-276.417</b>	<b>-1.290.929</b>	<b>-1.117.346</b>
Dividends	0	0	0	0
Transactions with owners	0	0	0	0
<b>Equity as at 31-12-2022</b>	<b>525.000</b>	<b>541.630</b>	<b>1.388.650</b>	<b>2.455.280</b>
<i>Statement of changes in equity</i>				
<i>01-01-2023 - 31-12-2023</i>				
Equity as at 01-01-2023	525.000	541.630	1.388.650	2.455.280
Net profit for the year	0	0	-1.708.694	-1.708.694
Capital increase	0	0	0	0
Capitalised development costs	0	-48.819	48.819	0
	<b>0</b>	<b>-48.819</b>	<b>-1.659.875</b>	<b>-1.708.694</b>
Dividends	0	0	0	0
Transactions with owners	0	0	0	0
<b>Equity as at 31-12-2023</b>	<b>525.000</b>	<b>492.811</b>	<b>-271.225</b>	<b>746.586</b>

## Cash flow statement

	31-12-2023	31-12-2022
	DKK	DKK
<b>Loss before tax</b>	-1.992.286	-1.338.626
Adjustment of non-cash transactions:		
Depreciation, amortisation and impairment losses, intangible assets	98.396	74.917
Financial expenses	15.953	25.889
Change in working capital:		
Receivables	-37.280	30.511
Trade payables	192.284	-559.146
Prepaid expenses	0	0
Other liabilities	37.000	19.426
Corporate tax	665.454	67.633
<b>Net cash from operating activities before net financials</b>	<b>-1.066.479</b>	<b>-1.679.397</b>
Financial expenses paid	-15.953	-25.889
<b>Net cash from operating activities</b>	<b>-1.036.432</b>	<b>-1.705.285</b>
Purchase of other intangible assets	0	0
Purchase of property, plant and equipment	0	0
<b>Net cash used in investing activities</b>	<b>0</b>	<b>0</b>
Repayment of loans	0	-58.019
Loans from shareholders	19.625	177.510
Capital Increase, net	0	0
<b>Net cash received from financing activities</b>	<b>19.625</b>	<b>119.490</b>
<b>Total cash flows for the year</b>	<b>-1.016.807</b>	<b>-1.585.795</b>
Cash equivalents beginning of year	1.242.369	2.828.164
<b>Cash equivalents end of year</b>	<b>225.562</b>	<b>1.242.369</b>
Cash and cash equivalents, end of year, comprises:		
Cash and cash equivalents	225.562	1.242.369
<b>Total</b>	<b>225.562</b>	<b>1.242.369</b>

1. Accounting policies
2. Nature of operations
3. Employee remuneration
4. Financial income and expenses
5. Tax
6. Intangible assets
7. Tangible assets and right-of-use assets
8. Financial assets and liabilities
9. Prepayments and other receivables
10. Cash and cash equivalent
11. Equity
12. The company's funding for 2024
13. Trade payables
14. Other liabilities
15. Contingent liabilities
16. Operating lease commitments
17. Financial risks and financial instruments
18. Events occurring after the balance sheet date

### 1. Accounting policies

#### 1.1 Basis of preparation

The financial statements of AKI Therapeutics A/S have been prepared in accordance with International Financial Reporting Standards ("IFRS"), as adopted by the EU, IFRIC interpretations and with those parts of the Danish Financial Statements Act applicable to companies reporting under IFRS.

IFRS is subject to amendment and interpretation by the IASB and the IFRS Interpretations Committee, and there is an on-going process of review and endorsement by the European Commission. These accounting policies comply with each IFRS that is mandatory for accounting periods ending on 31 December 2023.

The financial statements have been prepared on the going concern basis and have been prepared under the historical cost convention as modified by the revaluation of financial assets and liabilities including derivative financial instruments. The principal accounting policies set out below have been consistently applied to all periods presented.

#### 1.2 Foreign currency translation

##### *Functional and presentation currency*

The Financial Statements are presented in currency DKK, which is also the functional currency of the Company.

##### *Foreign currency transactions and balances*

Foreign currency transactions are translated into the functional currency, using the exchange rates prevailing at the dates of the transactions (spot exchange rate). Foreign exchange gains and losses resulting from the settlement of such transactions and from the re-measurement of monetary items denominated in foreign currency at year-end exchange rates are recognised in profit or loss.

Non-monetary items are not retranslated at year-end and are measured at historical cost (translated using the exchange rates at the transaction date), except for non-monetary items measured at fair value which are translated using the exchange rates at the date when fair value was determined.

#### 1.3 Revenue

No revenue is recognized in the financial statements.

#### 1.4 Research and development costs

Research and development costs primarily comprise internal and external costs related to development studies, employee costs and materials.

#### 1.5 Administrative costs

Administrative costs comprise costs incurred during the year concerning management and administration, including costs concerning administrative staff, the executive board, office premises, stationery and office supplies.

#### 1.6 Net financials

Net financials comprise interest, realised and unrealised capital gains and losses concerning financial assets and liabilities, amortisation of financial assets and liabilities, additions and reimbursements under the Danish tax prepayment scheme, etc. Financial income and expenses are recognised in the profit and loss account with the amounts that concerns the financial year.

### 1.7 Intangible assets

#### *Finalized development projects*

Patents and development costs recognised in the balance sheet are measured at cost less accrued amortization and writedowns for impairment. Development projects are amortized according to the straight-line method over their estimated useful lives from the time when the asset is ready for use. Patents and finalized development projects are amortized over 15 year based on the remaining lifetime of the patent. Amortization methods, useful years and residual values are reviewed every year.

Gain and loss from the sale of development projects, patents, and licenses are measured as the difference between the sales price with deduction of sales costs and the book value at the time of the sale. Gain or loss are recognised in the profit and loss account as other operating income or other operating expenses respectively.

### 1.8 Leased assets

#### *Operating leases*

The Company assesses whether a contract is or contains a lease at inception of the contract. The Company recognizes right-of-use assets and corresponding lease liabilities at the lease commencement date, except for short-term leases and leases of low value. For these leases, lease payments is recognized as an operating expense on a straight-line basis over the term of the lease.

The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liabilities adjusted for any lease payments made at or before the commencement date, plus initial costs incurred.

The right-of-use assets are subsequently measured at cost less accumulated depreciation and impairment losses.

The right-of-use assets are from the commencement date depreciated over the shorter period of lease term and useful life of the underlying asset. The estimated useful lives of right-of-use assets are determined on the same basis as those of the Company's corresponding assets such as property, plants and equipment. In addition, right-of-use assets are periodically reduced by impairment losses, if any, and adjusted in accordance with lease liabilities.

The lease liabilities are initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's incremental borrowing rate.

Lease payments included in the measurement of the lease liabilities comprise the following:

- Fixed payments.
- Variable payments, dependent on an index or rate.
- The exercise price of a purchase option if it is reasonably certain that the option will be exercised.
- Amounts expected to be payable under residual value guarantees.

The lease liabilities are subsequently measured at amortized cost using the effective interest method. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the estimate of the amount expected to be payable under a residual value guarantee, or if management changes its assessment of whether it will exercise a purchase, extension or termination option.

When the lease liabilities are remeasured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use assets, or is recorded in profit or loss if the carrying amount of the right-of-use assets has been reduced to zero.



### 1. Accounting policies - continued -

#### 1.9 Impairment testing of intangible assets and equipment

The carrying amount of both intangible and tangible assets are subject to an annual impairment assessment in order to disclose any indication of impairment beyond those expressed by amortisation and depreciation.

If indications of impairment are disclosed, impairment test are carried out for each individual asset or group of assets (cash-generating unit).

An impairment loss is recognised for the amount by which the asset's or cash-generating unit's carrying amount exceeds its recoverable amount, which is the higher of fair value less costs to sell and value-in-use. To determine the value-in-use, management estimates expected future cash flows from each cash-generating unit and determines a suitable interest rate in order to calculate the present value of those cash flows. The data used for impairment testing procedures are directly linked to the Company's latest approved budget, adjusted as necessary to exclude the effects of future reorganisations and asset enhancements. Discount factors are determined individually for each cash-generating unit and reflect management's assessment of respective risk profiles, such as market and asset-specific risks factors.

#### 1.10 Financial instruments

##### *Recognition, initial measurement and de-recognition*

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the financial instrument and are measured initially at fair value adjusted by transaction costs, except for those carried at fair value through profit or loss which are measured initially at fair value. Subsequent measurement of financial assets and financial liabilities are described below.

Financial assets are derecognised when the contractual rights to the cash flows from the financial asset expire, or when the financial asset and all substantial risks and rewards are transferred. A financial liability is derecognised when it is extinguished, discharged, cancelled or expires.

##### *Classification and subsequent measurement of financial assets*

For the purpose of subsequent measurement, financial assets other than those designated and effective as hedging instruments are classified into the following categories upon initial recognition:

- loans and receivables (amortized costs)
- financial assets at fair value through profit or loss (FVTPL)
- held-to-maturity (HTM) investments.

All financial assets except for those at FVTPL are subject to review for impairment at least at each reporting date to identify whether there is any objective evidence that a financial asset or a group of financial assets is impaired. Different criteria to determine impairment are applied for each category of financial assets, which are described below.

All income and expenses relating to financial assets that are recognised in profit or loss are presented within finance costs, finance income or other financial items, except for impairment of trade receivables which is presented within other expenses.

### 1. Accounting policies - continued -

#### *Loans and receivables*

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. After initial recognition, these are measured at amortised cost using the effective interest method, less provision for impairment. Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other receivables fall into this category of financial instruments.

Individually significant receivables are considered for impairment when they are past due or when other objective evidence is received that a specific counterparty will default. Receivables that are not considered to be individually impaired are reviewed for impairment in groups, which are determined by reference to the industry and region of a counterparty and other shared credit risk characteristics. The impairment loss estimate is then based on recent historical counterparty default rates for each identified group.

#### *Financial assets at FVTPL*

A financial asset is classified at fair value through profit or loss if it is classified as held for trading or is designated as such upon initial recognition. Financial assets are designated at fair value through profit or loss if the Company manages such investments and makes purchase and sale decisions based on their fair value in accordance with the Company's documented risk management or investment strategy. Upon initial recognition attributable transaction costs are recognised in profit or loss as incurred. Financial assets at fair value through profit or loss are measured at fair value, and changes therein are recognised in profit or loss.

#### *HTM investments*

HTM investments are non-derivative financial assets with fixed or determinable payments and fixed maturity other than loans and receivables. Investments are classified as HTM if the Company has the intention and ability to hold them until maturity. The Company do not currently hold any items designated into this category.

HTM investments are measured subsequently at amortised cost using the effective interest method. If there is objective evidence that the investment is impaired, determined by reference to external credit ratings, the financial asset is measured at the present value of estimated future cash flows. Any changes to the carrying amount of the investment, including impairment losses, are recognised in profit or loss.

#### **1.11 Income taxes**

Tax expense recognised in profit or loss comprises the sum of deferred tax and current tax not recognised in other comprehensive income or directly in equity.

Current income tax assets and/or liabilities comprise those obligations to, or claims from, fiscal authorities relating to the current or prior reporting periods, that are unpaid at the reporting date. Current tax is payable on taxable profit, which differs from profit or loss in the Financial Statements. Calculation of current tax is based on tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period.

Deferred income taxes are calculated using the liability method on temporary differences between the carrying amounts of assets and liabilities and their tax bases. However, deferred tax is not provided on the initial recognition of goodwill, or on the initial recognition of an asset or liability unless the related transaction is a business combination or affects tax or accounting profit. Deferred tax on temporary differences associated with investments in subsidiaries and joint ventures is not provided if reversal of these temporary differences can be controlled by the Group and it is probable that reversal will not occur in the foreseeable future.

Deferred tax assets and liabilities are calculated, without discounting, at tax rates that are expected to apply to their respective period of realisation, provided they are enacted or substantively enacted by the end of the reporting

### 1. Accounting policies - continued -

Deferred tax assets are recognised to the extent that it is probable that they will be able to be utilised against future taxable income, based on the Company's forecast of future operating results which is adjusted for significant non-taxable income and expenses and specific limits to the use of any unused tax loss or credit. Deferred tax liabilities are always provided for in full.

Deferred tax assets and liabilities are offset only when the Company has a right and intention to set off current tax assets and liabilities from the same taxation authority.

Changes in deferred tax assets or liabilities are recognised as a component of tax income or expense in profit or loss, except where they relate to items that are recognised in other comprehensive income, or directly in equity, in which case the related deferred tax is also recognised in other comprehensive income or equity, respectively.

#### 1.12 Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and demand deposits, together with other short-term, highly liquid investments that are readily convertible into known amounts of cash and which are subject to an insignificant risk of changes in value.

#### 1.13 Equity, reserves and dividend payments

Share capital represents the nominal value of shares that have been issued.

Share premium includes any premiums received on issue of share capital. Any transaction costs associated with the issuing of shares are deducted from share premium, net of any related income tax benefits.

Other components of equity include the following:

Reserve for capitalised development costs - comprises other development projects.

Retained earnings includes all current and prior period retained profits and share-based employee remuneration.

All transactions with owners are recorded separately within equity.

Dividend distributions payable to equity shareholders are included in other liabilities when the dividends have been approved in a general meeting prior to the reporting date.

#### 1.14 Provisions, contingent assets and contingent liabilities

Provisions for legal disputes, onerous contracts or other claims are recognised when the Company has a present legal or constructive obligation as a result of a past event and it is probable that an outflow of economic resources will be required from the Company and amounts can be estimated reliably. Timing or amount of the outflow may still be uncertain.

Provisions are measured at the estimated expenditure required to settle the present obligation, based on the most reliable evidence available at the reporting date, including the risks and uncertainties associated with the present obligation. Where there are a number of similar obligations, the likelihood that an outflow will be required in settlement is determined by considering the class of obligations as a whole. Provisions are discounted to their present values, where the time value of money is material.

Any reimbursement that the Company can be virtually certain to collect from a third party with respect to the obligation is recognised as a separate asset. However, this asset may not exceed the amount of the related provision.

In those cases where the possible outflow of economic resources as a result of present obligations is considered

### 1. Accounting policies - continued -

#### 1.15 Significant management judgement in applying accounting policies and estimation uncertainty

When preparing the financial statements, management undertakes a number of judgements, estimates and assumptions about the recognition and measurement of assets, liabilities, income and expenses.

##### *Impairment assesment*

In assessing impairment, management estimates the recoverable amount of each asset or cash-generating units based on expected future cash flows and uses an interest rate to discount them. Estimation uncertainty relates to assumptions about future operating results and the determination of a suitable discount rate (see note 1.9).

##### *Useful lives of non-current assets*

Management reviews its estimate of the useful lives of intangible and tangible non-current assets at each reporting date, based on the expected utility of the assets. Uncertainties in these estimates relate to technical obsolescence that may change the utility of certain software application systems (development projects).

### 2. Nature of operations

AKI Therapeutics A/S is a preclinical biotechnological company that focuses 100% on developing an effective, specific treatment for acute kidney injury. The company's drug candidate is a pioneering concept within this treatment area, which presents one of the biggest and most important challenges in the field of current intensive medical care.

There are currently no alternative treatments.

## Notes to the Financial Statements

### 3. Employee remuneration

Average number of employees in the year	2023 Number	2022 Number
Directors	1	1
<b>Total</b>	<b>1</b>	<b>1</b>

Remuneration of Directors and the Board of Directors	2023 DKK	2022 DKK
Remuneration of Directors	0	0
Remuneration of the Board of Directors	75.000	0
<b>Total remuneration for Directors</b>	<b>75.000</b>	<b>0</b>

### 4. Financial income and expenses

Financial income	2023 DKK	2022 DKK
Debt forgiveness	46.000	0
<b>Total</b>	<b>46.000</b>	<b>0</b>

Financial expenses	2023 DKK	2022 DKK
Interest expenses on liabilities measured at cost	15.953	25.889
<b>Total</b>	<b>15.953</b>	<b>25.889</b>

5. Tax	2023 DKK	2022 DKK
Tax on profit for the year:		
Current tax	-283.593	-238.716
Adjustment tax, previous years	0	7.363
Change in deferred tax	73.434	-124.975
Deferred tax asset not capitalized	-73.434	135.048
<b>Total</b>	<b>-283.593</b>	<b>-221.280</b>

#### Reconciliation of effective tax rate:

Loss/Profit before tax	-1.992.286	-1.338.626
Tax computed on the profit before tax at a tax rate of 22%	-438.303	-294.498
Permanent differences and not capitalized tax asset	154.710	65.855
Other adjustment to deferred tax	0	0
Adjustment tax, previous years	0	7.363
<b>Total - Effective tax rate (14,2%) (2022:16,5%)</b>	<b>-283.593</b>	<b>-221.280</b>

## Notes to the Financial Statements

	31-12-2023 DKK	31-12-2022 DKK
<b>Deferred tax is calculated as follows:</b>		
Deferred taxes arising from temporary differences are summarised below:		
Intangible assets	199.073	214.264
Taxable loss carried forward	-125.639	-349.312
Deferred tax asset not capitalized	-73.434	135.048
<b>Total deferred tax</b>	<b>0</b>	<b>0</b>
which is categorised as follows:		
<b>Non-current deferred tax</b>	<b>0</b>	<b>0</b>
<b>Current tax asset</b>		
Tax reimbursement, calculated for the year	283.593	238.716
Tax reimbursement, calculated last year	0	426.738
<b>Current tax asset, total</b>	<b>283.593</b>	<b>665.454</b>

### 6. Intangible assets

	Patents and licenses	Completed develop- ment projects	Total
<i>Financial year 2022</i>			
Cost as at 01-01-2022	333.998	789.763	1.123.760
<b>Cost as at 31-12-2022</b>	<b>333.998</b>	<b>789.763</b>	<b>1.123.760</b>
Amortisation and impairment losses as at 01-01-2022	22.266	52.651	74.917
Amortisation during the year	22.266	52.652	74.917
<b>Amortisation and impairment losses as at 31-12-2022</b>	<b>44.532</b>	<b>105.302</b>	<b>149.835</b>
<b>Carrying amount as at 31-12-2022</b>	<b>289.465</b>	<b>684.460</b>	<b>973.926</b>

## Notes to the Financial Statements

### 6. Intangible assets (continued)

	Patents and licenses	Completed develop- ment projects	Total
<i>Financial year 2023</i>			
Cost as at 01-01-2023	333.998	789.763	1.123.760
<b>Cost as at 31-12-2023</b>	<b>333.998</b>	<b>789.763</b>	<b>1.123.760</b>
Amortisation and impairment losses as at 01-01-2023	44.532	105.302	149.835
Amortisation during the year	45.745	52.651	98.396
<b>Amortisation and impairment losses as at 31-12-2023</b>	<b>90.277</b>	<b>157.953</b>	<b>248.231</b>
<b>Carrying amount as at 31-12-2023</b>	<b>243.720</b>	<b>631.809</b>	<b>875.530</b>

All recognized intangible assets have definite useful lives.

## Notes to the financial statements

### 7. Tangible assets and right-of-use assets

	Rent facilities	Total
<b>Right-of-use assets and lease liabilities</b>		
Cost as of January 1, 2022	163.372	163.372
Additions during the year	266.410	266.410
Depreciations during the year	-139.007	-139.007
<b>Right-of-use assets as of December 31, 2022</b>	<b>290.775</b>	<b>290.775</b>
Cost as of January 1, 2023	290.775	290.775
Additions during the year	333.197	333.197
Depreciations during the year	-201.816	-201.816
<b>Right-of-use assets as of December 31, 2023</b>	<b>422.156</b>	<b>422.156</b>
<b>Lease liabilities</b>		
	2023	2022
Current	207.954	143.236
Non-current	214.202	147.539
<b>Lease liabilities</b>	<b>422.156</b>	<b>290.775</b>
<b>Amounts included in the income statement</b>		
	2023	2022
Interest expense leases	15.959	10.992
Depreciation recognized on right-of-use assets	201.816	139.008
<b>Cost recognized for short term leases (less than 12 months)</b>	<b>217.775</b>	<b>150.000</b>

In 2023 the total cash outflow relating to leases was DKK 217.775, split between interests DKK 15.959 and repayment of DKK 201.816. In 2022 the total cash outflow relating to leases was DKK 150.000, split between interests DKK 10.992 and repayment of DKK 139.008.



## Notes to the Financial Statements

### 8. Financial assets and liabilities

Note 1.10 provides a description of each category of financial assets and financial liabilities and the related accounting policies. The carrying amounts of financial assets and financial liabilities in each category are as follows:

#### 31 December 2023

	Held for trading (FVTPL) (carried at fair value)	Loans and other receivables (carried at amortised cost)	Total
<b>Financial assets</b>			
Trade and other receivables	0	469.704	469.704
Cash and cash equivalents	0	225.562	225.562
<b>Other short term financial assets</b>	<b>0</b>	<b>695.266</b>	<b>695.266</b>
<b>Total financial assets</b>	<b>0</b>	<b>695.266</b>	<b>695.266</b>

	Derivatives measured at fair value (carried at fair value)	Other liabilities (carried at amortised cost)	Total
<b>Financial liabilities</b>			
Trade and other payables	0	1.032.162	1.032.162
Long term liabilities	0	214.202	214.202
<b>Financial liabilities</b>	<b>0</b>	<b>1.246.364</b>	<b>1.246.364</b>

#### 31 December 2022

	Held for trading (FVTPL) (carried at fair value)	Loans and other receivables (carried at amortised cost)	Total
<b>Financial assets</b>			
Trade and other receivables	0	814.286	814.286
Cash and cash equivalents	0	1.242.369	1.242.369
<b>Other short term financial assets</b>	<b>0</b>	<b>2.056.655</b>	<b>2.056.655</b>
<b>Total financial assets</b>	<b>0</b>	<b>2.056.655</b>	<b>2.056.655</b>

## Notes to the Financial Statements

### 8. Financial assets and liabilities - continued -

31 December 2022

	Other liabilities (carried at amortised cost)	Total
<b>Financial liabilities</b>		
Trade and other payables	718.536	718.536
Long term liabilities	147.539	147.539
<b>Financial liabilities</b>	<b>866.075</b>	<b>866.075</b>

Financial assets and liabilities measured at fair value, the methods used to measure fair value are described in accounting policies, note 1.10.

All of the above financial assets and liabilities carrying values are approximate to their fair values due to their short term nature as at 31 December 2023 and 31 December 2022 with the exception of held for trading assets and derivative financial instruments which are carried at their fair values.

### 9. Prepayments and other receivables

	31-12-2023 DKK	31-12-2022 DKK
Prepayments	0	0
Accruals	0	0
Other receivables	186.112	148.832
<b>Financial assets</b>	<b>186.112</b>	<b>148.832</b>

### 10. Cash and cash equivalent

	31-12-2023 DKK	31-12-2022 DKK
Cash	225.562	1.242.369
<b>Total</b>	<b>225.562</b>	<b>1.242.369</b>

### 11. Equity

#### *Share capital*

The Company's share capital consists of 5.250.000 ordinary shares of DKK 0,10 each. The shares are fully paid in. All shares are equally eligible to receive dividends and the repayment of capital and represent one vote at the shareholders' meeting.

#### *Retained earnings*

Retained earnings represent retained profits.

#### *Reserve for capitalised development costs*

Reserve for capitalised development costs represent the development costs, recognised in the balance sheet, from January 1, 2016, less deferred tax.

#### *Capital management policies and procedures*

The Company's capital management objectives are to ensure its ability to continue as a going concern and to provide an adequate return to shareholders.

The Company monitors capital on the basis of the carrying amount of equity plus borrowings, less cash and cash equivalents as presented on the statement of financial position.

The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. In order to maintain or adjust the capital structure, the Company may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares or sell assets to reduce debt.

### 12. The Company's funding for 2024

Based on management's budget for 2024 AKI Therapeutics A/S has sufficient capital resources to carry through the operational activities as planned for 2024. The capital resources include a credit facility from Finansmanagement ApS.

The Company expect to secure the necessary capital resources through issuance of capital instruments.

### 13. Trade payables

	31-12-2023	31-12-2022
	DKK	DKK
Trade payables	517.208	324.925
<b>Trade and other payables - current</b>	<b>517.208</b>	<b>324.925</b>

## Notes to the Financial Statements

### 14. Other liabilities

	31-12-2023 DKK	31-12-2022 DKK
Taxes and other social securities	0	0
Other liabilities	82.000	45.000
Loan from shareholders	225.000	205.375
Lease liabilities	207.954	143.236
<b>Other liabilities - current</b>	<b>514.954</b>	<b>393.611</b>

### 15. Contingent liabilities

Based on management's assesment, the Company is not involved in any lawsuits, arbitration cases or other matters which could have a material impact on the Company's financial position or result of operations (2022: DKK 0).

### 16. Operating lease commitments

The Company's annual rent obligation amounts to TDK 218 (2022: TDK 150).

### 17. Financial risks and financial instruments

#### *Risk management policy*

Management manages the Company's financial risks. The management of the Company's risks is included in the management's day-to-day monitoring of the Company. The Company is exposed to few financial risks, which result from its operating activities. The company does not actively engage in the trading of financial assets and financial derivatives.

#### *Credit risk*

Due to the nature of the business, credit risk is deemed minimal. The maximum credit risk relating to receivables corresponds to the carrying amount.

#### *Interest rate risks*

The Company is only exposed to interest rate risks in connection with deficit liquidity, as the Company only have loans from shareholders, the risk is deemed minimal.

#### *Foreign currency risk*

The Company is subject to currency risks on payables and receivables in foreign currency, and purchases of services in foreign currency. The Company's foreign trade is minimal.

## Notes to the Financial Statements

### 17. Financial risks and financial instruments - continued -

#### Liquidity risk

The Company liquidity risks covers the risk that the Company is not able to meet its liabilities as they fall due. The Company is not subject to material liquidity risks. Reference is made to the information in note 12.

The maturities of financial liabilities appear from the tables below. All amounts are contractual cash flows, i.e. inclusive of interest.

	Within 1 year	1-2 year(s)	2-5 years	Over 5 years	Total
As at 1 January 2023					
Loan from shareholders	205.375	0	0	0	205.375
Trade payables	324.925	0	0	0	324.925
Other payables	188.236	0	0	0	188.236
<b>Total</b>	<b>718.536</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>718.536</b>

All financial liabilities as at 1 January 2023 are measured at amortised cost.

	Within 1 year	1-2 year(s)	2-5 years	Over 5 years	Total
As at 31 December 2023					
Loan from shareholders	225.000	0	0	0	225.000
Trade payables	517.208	0	0	0	517.208
Other payables	289.954	0	0	0	289.954
<b>Total</b>	<b>1.032.162</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1.032.162</b>

All financial liabilities as at 31 December 2023 are measured at amortised cost.

### 18. Events occurring after the balance sheet date

There were no post balance sheet events requiring adjustment to the Financial Statements.

# PENNEO

Underskrifterne i dette dokument er juridisk bindende. Dokumentet er underskrevet via Penneo™ sikker digital underskrift. Underskrivernes identiteter er blevet registreret, og informationerne er listet herunder.

"Med min underskrift bekræfter jeg indholdet og alle datoer i dette dokument."

## Søren Nielsen

Direktør

På vegne af: AKI Therapeutics A/S

Serienummer: eeda17cd-37e3-4213-8b48-19890c34d612

IP: 109.59.xxx.xxx

2024-06-12 10:30:18 UTC



## Martin Bornholtz

Grant Thornton, Godkendt Revisionspartnerselskab CVR: 34209936

Statsautoriseret revisor

På vegne af: Grant Thornton

Serienummer: 07f98b67-f881-4b5f-ae57-2e18b964bfa1

IP: 62.243.xxx.xxx

2024-06-12 10:31:34 UTC



## Christian Vinding Thomsen

Bestyrelsesmedlem

På vegne af: AKI Therapeutics A/S

Serienummer: 29cc3928-e143-47f7-be20-a163dd10b9e3

IP: 80.209.xxx.xxx

2024-06-12 13:01:12 UTC



## Troels Peter Troelsen

Bestyrelsesformand

På vegne af: AKI Therapeutics A/S

Serienummer: 6bb7f296-4d57-43d8-b2ac-470932eb3a3f

IP: 212.130.xxx.xxx

2024-06-12 14:37:07 UTC



Dette dokument er underskrevet digitalt via Penneo.com. Signeringsbeviserne i dokumentet er sikret og valideret ved anvendelse af den matematiske hashværdi af det originale dokument. Dokumentet er låst for ændringer og tidsstemplet med et certifikat fra en betroet tredjepart. Alle kryptografiske signeringsbeviser er indlejret i denne PDF, i tilfælde af de skal anvendes til validering i fremtiden.

### Sådan kan du sikre, at dokumentet er originalt

Dette dokument er beskyttet med et Adobe CDS certifikat. Når du åbner dokumentet

i Adobe Reader, kan du se, at dokumentet er certificeret af Penneo e-signature service <penneo@penneo.com>. Dette er din garanti for, at indholdet af dokumentet er uændret.

Du har mulighed for at efterprøve de kryptografiske signeringsbeviser indlejret i dokumentet ved at anvende Penneos validator på følgende websted: <https://penneo.com/validator>